Study: Brilinta outperforms Plavix in treating heart attack patients
Researchers found AstraZeneca's Brilinta more effective than Bristol-Myers Squibb's Plavix in curbing serious cardiovascular events without increasing the risk of bleeding in a study of more than 8,000 heart attack patients. The result might not be enough to guarantee regulatory approval for Brilinta, which was also linked to breathlessness in the trial.
Reuters
| 11/15
This story published in FMI Pharmacy dailyLead on 11/16/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|